JPMorgan double downgraded Fulcrum Therapeutics to Underweight from Overweight without a price target citing the discontinuation of the company's lead asset pociredir in sickle cell disease. As the company undergoes a strategic review, the shares will be a relative underperformer, the analyst tells investors in a research note.
